Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 13/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | FABP3 | P05413 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5007776 | 0.97 | ADORA1 (0.56) | ADORA1ADORA2AADORA2BSMN1; SMN2ADORA3 | |
| SCHEMBL5008518 | 0.93 | ADORA1 (0.60) | ADORA1ADORA2AADORA2BADORA3 | |
| SCHEMBL5008390 | 0.93 | ADORA1 (0.55) | ADORA1ADORA2AADORA2BSMN1; SMN2ADORA3 | |
| SCHEMBL5005398 | 0.90 | ADORA1 (0.54) | ADORA1ADORA2AADORA2BSMN1; SMN2ADORA3 | |
| SCHEMBL5007761 | 0.85 | ADORA1 (0.52) | ADORA1ADORA2AADORA2BSMN1; SMN2ADORA3 | |
| SCHEMBL5008556 | 0.78 | ADORA1 (0.78) | ADORA1ADORA2AADORA2BSMN1; SMN2ADORA3 | |
| SCHEMBL5007752 | 0.77 | GFER (0.55) | ADORA1ADORA2AADORA2BSMN1; SMN2ADORA3 | |
| SCHEMBL5005326 | 0.75 | ADORA1 (0.58) | ADORA1ADORA2AADORA2BGFERLMNA | |
| SCHEMBL5010555 | 0.74 | GFER (0.61) | ADORA1ADORA2AADORA2BGFERKDM4E | |
| SCHEMBL5005161 | 0.74 | GFER (0.80) | ADORA1ADORA2AADORA2BGFERKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | ADORA1 749/4885ADORA2A 1361/4885ADORA2B 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.